Shinobi Therapeutics, a trailblazer in immune evasive iPS cell therapies, has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). This significant grant will accelerate the development of Shinobi’s pioneering iPS-T cell therapy, aimed at treating GPC3+ solid tumors. Dr. Yasumichi Hitoshi, Chief of…
AIRNA, a cutting-edge biotech firm specializing in RNA editing therapeutics, has successfully closed an oversubscribed $60 million Series A financing round, pushing the total raised to $90 million. This investment, led by Forbion and supported by a prestigious group of investors including ARCH Venture Partners, Ono Venture Investment, Alexandria Venture Investments, and ND Capital, will…
Jade Biosciences, a biotechnology innovator focused on autoimmune diseases, has announced the successful closing of an $80 million financing round. Led by Fairmount and Venrock Healthcare Capital Partners, with additional contributions from Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP, this investment will drive the development of Jade’s cutting-edge therapies…
LTZ Therapeutics, an emerging leader in immunotherapy, has successfully completed a $20 million Series A financing round. This round, spearheaded by new investor Lapam Capital and including significant contributions from GL Ventures, K2 Venture Partners, and Shunwei Capital, brings LTZ’s total funding to approximately $50 million since its inception in 2022. The new capital will…
In a major boost to healthcare innovation, SymBiosis and HealthTech Arkansas have announced the launch of the biophyle Trial Accelerator, a pioneering initiative aimed at bridging the gap between cutting-edge clinical-stage biotherapeutics and Arkansas’ healthcare ecosystem. This strategic program is designed to catalyze the commercialization of novel treatments by connecting biotherapeutic innovations with clinical trial…
Pinetree Therapeutics, Inc., a trailblazer in targeted protein degradation (TPD) technology, has successfully closed a Series A funding round, raising $17 million to advance its AbReptor™ platform. This investment round was co-led by STIC Investments and DSC Investment, with new participation from Atinum Investment, Quantum FA, and S&S Investment, alongside existing backers DSC Investment, Schmidt,…
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a leader in the development of cutting-edge bacteriophage therapies, has been awarded an additional $5.25 million in non-dilutive funding by the U.S. Department of Defense (DoD). This significant grant, facilitated through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) and the Joint…
Spear Bio Inc., an innovative biotechnology company specializing in ultra-sensitive protein detection, has successfully closed an oversubscribed $45 million Series A financing round. The investment was co-led by Foresite Capital and Bio-Techne Corporation, with additional support from Maverick Ventures, Yonjin Capital, and CDH Investments. Vikram Bajaj, Managing Director at Foresite Capital, will join Spear Bio’s…
Shenzhen Synthetica Pioneering Co., Ltd. has successfully concluded a Series A funding round, raising significant capital to propel its innovative oncolytic bacterial therapy into clinical trials. This funding milestone, spearheaded by prominent investors including Boehringer Ingelheim Venture Fund and Temasek, along with contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund, underscores the…
Truvian Health, a pioneering force in healthcare innovation, has announced a significant milestone with the successful closure of a $74 million funding round aimed at revolutionizing the accessibility of blood testing. This funding, led by Wittington Ventures and Great Point Ventures, marks a pivotal moment for Truvian as it prepares to advance its groundbreaking blood…
